Company Adocia

Equities

ADOC

FR0011184241

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Ratings for Adocia

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Euronext Paris Other stock markets 11:35:09 2024-07-12 am EDT			5-day change	1st Jan Change
5.44 ^EUR	-3.72%		-23.27%	-52.86%

Jul. 11	ADOCIA : price target reduced by Oddo BHF	CF
Jul. 10	Adocia, Tonghua Dongbao End Insulin Combo License Deal	MT

Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes.

At the end of 2023, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram-ADO09 and BioChaperone Glucagon) and 3 preclinical-stage products (BioChaperone® LisPram, BioChaperone® Glargine GLP-1 and BioChaperone® Glucagon GLP-1).

Number of employees: 78

EUR in Million	2022	Weight	2023	Weight	Delta
Pre-approved Therapeutic Proteins 100.0 %	11	100.0 %	2	100.0 %	-81.22%

EUR in Million	2022	Weight	2023	Weight	Delta
France 100.0 %	11	100.0 %	2	100.0 %	-81.22%

Managers	Title	Age	Since
Olivier Soula FOU	Founder	53	05-12-15
Gérard Soula FOU	Founder	78	05-12-15
Valérie Danaguezian DFI	Director of Finance/CFO	-	05-12-31
Géraldine Favre-Soula HRO	Human Resources Officer	-	-

Members of the board	Title	Age	Since
Gérard Soula FOU	Founder	78	05-12-15
Katherine Bowdish BRD	Director/Board Member	67	21-05-20
Ekaterina Smirnyagina BRD	Director/Board Member	58	13-06-17
Stéphane Boissel BRD	Director/Board Member	56	21-05-20
Olivier Soula FOU	Founder	53	05-12-15
Mads Dall BRD	Director/Board Member	-	-
Claudia Mitchell BRD	Director/Board Member	-	21-05-20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	14,089,930	11,764,137 ( 83.49 %)	2,547 ( 0.0181 %)	83.49 %

Name	Equities	%	Valuation
Vester Finance SA 10.43 %	1,536,274	10.43 %	13 M €
Gérard Soula 8.398 %	1,237,226	8.398 %	10 M €
BPIFrance Investissement SAS 4.675 %	688,666	4.675 %	6 M €
Société Hospitalière d'Assurances Mutuelles SAM 2.172 %	320,000	2.172 %	3 M €
Olivier Soula 2.106 %	310,190	2.106 %	3 M €
Oreo Finance SASU 0.2753 %	40,561	0.2753 %	339 076 €
Uzes Gestion SA 0.2036 %	30,000	0.2036 %	250 790 €
ACG Management SAS 0.1739 %	25,618	0.1739 %	214 158 €
ADOCIA 0.0173 %	2,547	0.0173 %	21 292 €
Gestys SA 0.007467 %	1,100	0.007467 %	9 196 €

Name	Equities	%	Valuation
ADOCIA 0.02%	2,547	0.02%	21,292 $

Adocia SA

115 avenue Lacassagne

69003, Lyon

+33 4 72 61 06 10

http://www.adocia.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

5.44 EUR

Average target price

6.3 EUR

Spread / Average Target

+15.81%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ADOCIA	-52.86%	89.23M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs